GB0525618D0 - Method - Google Patents

Method

Info

Publication number
GB0525618D0
GB0525618D0 GB0525618A GB0525618A GB0525618D0 GB 0525618 D0 GB0525618 D0 GB 0525618D0 GB 0525618 A GB0525618 A GB 0525618A GB 0525618 A GB0525618 A GB 0525618A GB 0525618 D0 GB0525618 D0 GB 0525618D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0525618A
Other versions
GB2421730A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of GB0525618D0 publication Critical patent/GB0525618D0/en
Publication of GB2421730A publication Critical patent/GB2421730A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C12Q1/6802—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
GB0525618A 2004-12-21 2005-12-16 Method for evaluating pharmacological target related toxicity Withdrawn GB2421730A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0427916A GB0427916D0 (en) 2004-12-21 2004-12-21 Method

Publications (2)

Publication Number Publication Date
GB0525618D0 true GB0525618D0 (en) 2006-01-25
GB2421730A GB2421730A (en) 2006-07-05

Family

ID=34090411

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0427916A Ceased GB0427916D0 (en) 2004-12-21 2004-12-21 Method
GB0525618A Withdrawn GB2421730A (en) 2004-12-21 2005-12-16 Method for evaluating pharmacological target related toxicity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0427916A Ceased GB0427916D0 (en) 2004-12-21 2004-12-21 Method

Country Status (1)

Country Link
GB (2) GB0427916D0 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921712D0 (en) 2009-12-11 2010-01-27 Ge Healthcare Uk Ltd Methods of detecting DNA damage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4095895B2 (en) * 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Short RNA molecules that mediate RNA interference
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP4304309B2 (en) * 2002-05-30 2009-07-29 レイベン バイオテクノロジーズ，インコーポレイティド Animal models for toxicology and medication prediction
GB0216203D0 (en) * 2002-07-12 2002-08-21 Imp Cancer Res Tech Mondulation of cytochrome P450 reductase activity

Also Published As

Publication number Publication date
GB0427916D0 (en) 2005-01-19
GB2421730A (en) 2006-07-05

Similar Documents

Publication Publication Date Title
GB0420061D0 (en) Method
GB0402639D0 (en) Method
GB0410478D0 (en) Method
GB0422733D0 (en) Method
GB0415009D0 (en) Method
GB0418651D0 (en) Method
GB0422730D0 (en) Method
GB0419419D0 (en) Method
GB0412659D0 (en) Method
GB0412672D0 (en) Method
GB0420815D0 (en) Method
GB0414787D0 (en) Method
GB0423871D0 (en) Method
GB0405751D0 (en) Method
GB0419405D0 (en) Method
GB0428327D0 (en) Method
GB0415081D0 (en) Method
GB0525618D0 (en) Method
GB0413714D0 (en) Method
GB0406833D0 (en) Method
GB0423424D0 (en) Method
GB0410872D0 (en) Method
GB0406989D0 (en) Method
GB0405176D0 (en) Method
GB0405730D0 (en) Method

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)